Amgen Inc. v. F. Hoffmann-LaRoche LTD et al

Filing 343

Defendants' Reply in Opposition to Amgen Inc.'s Claims Construction Brief [DN 323] - LEAVE TO FILE GRANTED ON 3/30/07 Response by F. Hoffmann-LaRoche LTD, Roche Diagnostics GmbH, Hoffmann LaRoche Inc. to #323 Response,,,,,. (Attachments: #1 Index of Exhibits#2 Exhibit RR#3 Exhibit SS (part 1)#4 Exhibit SS (part 2)#5 Exhibit TT#6 Exhibit UU#7 Exhibit UU-1#8 Exhibit UU-2#9 Exhibit UU-3)(Rizzo, Nicole)

Amgen Inc. v. F. Hoffmann-LaRoche LTD et al

Doc. 343 Att. 1

Case 1:05-cv-12237-WGY

Document 343-2

Filed 03/30/2007

Page 1 of 2

Index of Exhibits
Exhibit A Exhibit B Exhibit C Exhibit D Exhibit E Exhibit F Exhibit G Exhibit H Exhibit I Exhibit J Exhibit K Exhibit L Exhibit M Exhibit N Exhibit O Exhibit P Exhibit Q Exhibit R Exhibit S Exhibit T Exhibit U Exhibit V Exhibit W Exhibit X Exhibit Y Exhibit Z Exhibit AA Exhibit BB Exhibit CC Exhibit DD Exhibit EE Exhibit FF Exhibit GG Exhibit HH Exhibit II Exhibit JJ Exhibit KK Exhibit LL U.S. Patent Nos. 5,441,868 U.S. Patent Nos. 5,547,933 U.S. Patent Nos. 5,618,698 U.S. Patent Nos. 5,621,080 U.S. Patent Nos. 5,756,349 U.S. Patent Nos. 5,955,422 Expert Declaration of Thomas R. Kadesch, Ph.D., Professor of Genetics at the University of Pennsylvania School of Medicine, and attached exhibits. May 5, 1999, Amendment, 08/100,197-33. Goldwasser Depo. Tr. February 14, 2007 March 31, 1995, Office Action, 08/100,197-26 February 10, 1989, Office Action, 07/113,178-9. June 2, 1989, Amendment Under Rule 116, 07/113,178-11 May 24, 1988, Second Preliminary Amendment, 07/113,179-8. September 1, 1993, Office Action, 07/113,179-29. January 10, 1994, Amendment and Response, 07/113,179-33. Brief for Lin in Interference No. 102,097. U.S. Patent No. 4,399,216. MANUAL OF PATENT EXAMINING PROCEDURE § 2173.05(h) I. MANUAL OF PATENT EXAMINING PROCEDURE § 608.01(p) Completeness [R-3]. February 27, 2007 Letter From Thomas Fleming to Deborah E. Fishman. U.S. Patent No. 4,703,008. U.S. Patent No. 6,583,272. Pollack, A., "Rivals Laying Siege to Amgen's Near Monopoly in Anemia Drugs," The New York Times, Dec. 23, 2005. November 30, 1984, Application No. 06/675,298. June 16, 1986, Office Action, 06/675,298-8. June 18, 1987 Office Action, 06/675,298-17. July 10, 1987, Amendment and Reply, 06/675,298-20. October 23, 1987, Application No. 07/113,178. June 2, 1988, Office Action, 07/113,178-4. June 2, 1989, Amendment Under Rule 116, 07/113,178-11. June 20, 1989, Office Action, 07/113,178-13. July 12, 1989, Amendment, 07/113,178-15. December 12, 1989, Examiner Interview, 07/113,178-17. January 1, 1990, Amendment Under Rule 116, 07/113,178-19. May 24, 1988, Second Preliminary Amendment, 07/113,179-8. September 27, 1988, Applicant's Reply, 07/113,179-14. Goldwasser Depo. Tr. February 14, 2007 Morgan Stanley Equity Research, "Amgen: Some Setbacks for Competitors in EU," Feb. 26, 2006.

Dockets.Justia.com

Case 1:05-cv-12237-WGY

Document 343-2

Filed 03/30/2007

Page 2 of 2

Exhibit MM Exhibit NN Exhibit OO Exhibit PP Exhibit QQ Exhibit RR Exhibit SS Exhibit TT Exhibit UU
03099/00501 644853.1

Amgen Inc. v. Hoechst Marion Roussel Inc., No. 97-10814 (D. Mass.), Trial Tr. (June 7, 2000). MANUAL OF PATENT EXAMINING PROCEDURE § 2111.03 [R-3]. THE AMERICAN HERITAGE DICTIONARY 1399 (4th ed. 2006). Supplemental Expert Declaration of Thomas R. Kadesch, Ph.D., Professor of Genetics at the University of Pennsylvania School of Medicine, and attached exhibits. December 11, 1996, Interview Summary, 0-8/468,381-7. J. C. Egrie et al., Characterization and Biological Effects of Recombinant Human Erythropoietin, 172 IMMUNOBIOLOGY 213 (1986)., pp 213-224, 217-218, (1986) October 23, 1987, Declaration Pursuant to 37 C.F.R. § 1.132, 113,178 WEBSTER'S II DICTIONARY (3d ed. 2005). Expert Declaration of Patrick P. Deluca, Ph.D., and attached exhibits.